Recent Press and News Releases 

CVBT Announces Appointments to Scientific and
Medical Advisory Board

Annual Shareholder Meeting Results

Notice of CVBT Annual Meeting On 7/10/18

Notice of CVBT Annual Meeting

CVBT 2016 Annual Shareholders Meeting

Notice of CVBT Annual Meeting of Stockholders
on 11/14/2016

Notice of CVBT Annual Meeting
on 11/14/2016

CVBT is pleased to announce that its new home,
Texas, is continuing to accelerate its growth in
the Biotech industry.

CVBT Moves Headquarters to Texas

Cardiovascular Disease - a Global Epidemic - The World Health Organization has declared cardiovascular disease a Global Epidemic.  Cardiovascular Disease (CVD) is the number 1 cause of death in the world. CVD is responsible for 30% of all deaths in the world.  Ischemic heart disease (blockage of the microvascular system in the heart), chronic dermal ulcers and peripheral artery disease (complications of diabetes), and stroke are leading causes of death from CVD.

The Solution to the Global Epidemic - Angiogenesis through CVBT’s Drug Candidates - Cardiovascular diseases are a result of restricted or lack of blood flow to tissues or organs.  Angiogenesis is the growth of new blood vessels to tissue or organs.  Angiogenesis medical solutions are predicted to have the same impact in the 21st century that antibiotics had in the 20th century (Angiogenesis Foundation). CardioVascular BioTherapeutics’ (CVBT’s) therapeutic drug candidates stimulate angiogenesis.  When areas of the body are ischemic, receiving an insufficient supply of blood, angiogenesis can grow new blood vessels to the region or bypass areas that are blocked. This is the underlying science of CVBT’s active pharmaceutical ingredient (API). CVBT’s drug candidates trigger the healing process, or angiogenesis, by introducing the protein at the exact location of damage, blockage, or lack of blood vessels.

©2015 CardioVascular BioTherapeutics, Inc.